MarketCap
Facebook
X
TelegramAdamas Pharmaceuticals, Inc. DSO Ratio | ADMS
Annual DSO Ratio Adamas Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 45.6 | 47 | 68.1 | 878 | 614 | 1.06 K | 3.42 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.06 K | 3.42 | 388 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Relay Therapeutics
RLAY
|
2.19 | $ 19.81 | -2.87 % | $ 3.4 B |  USA |
 |
Precigen
PGEN
|
91.2 | $ 4.51 | -4.76 % | $ 1.41 B | USA |
 |
Avidity Biosciences
RNA
|
18.5 | $ 8.23 | -1.79 % | $ 1.13 B | USA |
 |
Ocular Therapeutix
OCUL
|
221 | $ 6.62 | -3.36 % | $ 1.24 B | USA |
 |
Outlook Therapeutics
OTLK
|
192 | $ 0.46 | -0.84 % | $ 16 M | USA |
 |
uniQure N.V.
QURE
|
2.3 | $ 22.7 | -0.39 % | $ 1.31 B |  Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
75.9 | $ 16.13 | -1.71 % | $ 1.59 B | USA |
 |
Rafael Holdings
RFL
|
224 | $ 1.11 | 2.45 % | $ 57 M | USA |
 |
REGENXBIO
RGNX
|
53.1 | $ 7.66 | -5.08 % | $ 395 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
57.9 | $ 43.83 | 4.22 % | $ 788 M | USA |
 |
SELLAS Life Sciences Group
SLS
|
72 | $ 8.38 | -2.39 % | $ 914 M | USA |
 |
Celsion Corporation
CLSN
|
15.6 | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
-27.2 | - | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
566 | $ 1.69 | -5.34 % | $ 66.3 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
118 | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
47.3 | $ 1.62 | -3.57 % | $ 89.7 M | USA |
 |
Stoke Therapeutics
STOK
|
7.52 | $ 27.16 | -1.98 % | $ 1.61 B | USA |
 |
Sutro Biopharma
STRO
|
22.4 | $ 10.08 | -5.0 % | $ 85.7 M | USA |
 |
Soligenix
SNGX
|
87.4 | $ 0.32 | -6.35 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
823 | $ 42.54 | -1.0 % | $ 48.7 B |  Israel |
 |
China SXT Pharmaceuticals
SXTC
|
358 | $ 2.99 | -3.55 % | $ 2.03 M | China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
79.3 | $ 20.9 | -0.9 % | $ 33 B |  Japan |
 |
Supernus Pharmaceuticals
SUPN
|
83.7 | $ 28.77 | 4.15 % | $ 1.62 B | USA |
 |
Galapagos NV
GLPG
|
56.5 | - | - | $ 1.83 B | Belgium |
 |
Savara
SVRA
|
2.41 K | $ 4.92 | -2.57 % | $ 1.09 B | USA |
 |
Teligent, Inc.
TLGT
|
90.7 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
169 | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
129 | $ 64.27 | 1.4 % | $ 9.28 B | USA |